Dopamine transporter: nootropics and compounds | sci-wiki

Fluorene Myristate

Fluorene myristate is an obscure research compound marketed as a nootropic; based on its name and vendor descriptions it appears to be a myristic-acid ester of a fluorene or fluorenol core, likely intended as a lipophilic prodrug or slow-release form of 9-fluorenol (hydrafinil), a weak dopamine reuptake inhibitor and modafinil metabolite. There is no primary peer-reviewed literature on fluorene myristate itself, and even its exact structure and CAS identity are inconsistently reported by suppliers. This entry is therefore deliberately cautious and does not assert mechanisms or effects that have not been demonstrated for this specific molecule.

reference

Nootropic

JJC8-088

JJC8-088 is a modafinil-derived dopamine transporter blocker synthesised at NIDA that was first published as an atypical, low abuse liability lead for cocaine use disorder and was then reclassified by its own lab as the cocaine-like one [2]; rats and monkeys self-administer it, no human has ever taken it, and its role in the literature today is mostly as the typical comparator against its atypical sibling JJC8-091 [4].

reference

Nootropic

MRZ-9547

MRZ-9547 is the R-enantiomer of phenylpiracetam (R-fonturacetam), developed by Merz Pharmaceuticals as a selective dopamine transporter (DAT) inhibitor for the fatigue and reduced motivation of Parkinson's disease [1][2]. In rats it dose-dependently increases effort-related responding and reverses motor deficits in Parkinson models, moderately raising striatal dopamine release, while its L-enantiomer MRZ-9546 is far less active [1][2]. It should not be conflated with racemic phenylpiracetam: MRZ-9547 is a single, defined enantiomer studied specifically as a DAT-based anti-fatigue agent [2].

reference

Antidepressant

NS-2359

NS-2359 (GSK372475) is a triple monoamine reuptake inhibitor with approximately equipotent blockade of the dopamine, norepinephrine, and serotonin transporters, originally developed by NeuroSearch and licensed to GlaxoSmithKline [1]. It was investigated as a broad-spectrum antidepressant and for other neuropsychiatric indications, but two controlled trials in major depressive disorder found it neither efficacious nor well tolerated [1].

reference